Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

March 7, 2022

PSMA-Targeted Treatment Improves Bone-Related Pain in Metastatic, Castration-Resistant Prostate Cancer

Author(s):

Brielle Benyon
Conference|ASCO Genitourinary Symposium

Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.

Prostate cancer that spreads to the bones can cause patients to feel aches and pains, putting a major burden on their day-to-day life. However, recent research showed that patients treated with Lutetium-177 PSMA-617 tended to not only have better survival outcomes, but improved bone pain-related quality of life, too.

Researchers surveyed 50 men with metastatic, castration-resistant prostate cancer who were being treated with Lutetium-177 PSMA-617, a prostate-specific membrane antigen (PSMA)-targeted radionuclide, with a focus on their pain related to bone metastases and overall quality of life. Their findings were presented at the 2022 ASCO Genitourinary Cancers Symposium.

“We found that men who completed the survey on bone-metastasis-related pain and quality of life reported improvements, on average, in bone-metastasis-related pain and their ability to function despite that pain,” said study author Brian D. Gonzalez, a Health Outcomes and Behavior researcher at the Moffitt Cancer Center in Tampa, Florida, in an interview with CURE®’s sister publication, Urology Times®.

At the follow-up, which was six or 12 weeks after their final injection with Lutetium-177 PSMA-617, 37 patients were still alive, and 25 provided data that was able to be evaluated regarding bone metastasis-related pain. Ten patients (40%) said that they reported less functional interference from their pain, as well as lower pain consistency, intermittency and difficulty alleviating pain over time.

On average, patients saw the biggest increase in functional ability despite bone pain from baseline to the second cycle of treatment.

Not only did this study find an improvement in quality of life, but previous research has shown that treatment with Lutetium-177 PSMA-617 also tends to improve progression-free survival (defined as the time between treatment and a patient’s disease getting worse), overall survival and patient-reported outcomes. However, more work needs to be done since not all patients involved in the study were able to provide data on their pain.

“A caveat is that there were several patients who were unable to complete the survey in this longitudinal study because some of them had passed away, or some of them felt unwell or were unwilling or unable to attend visits,” Gonzalez mentioned.

Regardless of the type of treatment that they are undergoing, Gonzalez stressed that having open communication with the clinicians regarding bone pain or any other cancer-related symptoms is essential.

“The number one thing to do if patients are experiencing pain or any other symptom or toxicity during treatment is to let their medical team know,” he said. “To let the oncologist or provider know (about the pain) allows the provider to discuss whether this is expected or uncommon, but more importantly, what they can do about it.”

Gonzalez said that one of the main goals of this study was to ensure that patients were being open with their treatment team, which can lead to better management of symptoms.

“That’s the purpose of this and many other projects, which is to empower patients to report their symptoms and therefore get treatment for them and get those issues resolved,” he concluded.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Imiage of two doctors with text.
Image of two doctors and text.
Image of patient and doctor.
Image of two doctors with text.
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of thumbnail.
Image of doctor.
Related Content
Advertisement
Image of prostate model.
June 27th 2025

June Prostate Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data on the role of AI in care.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of Dr. Ravi, with text,
June 26th 2025

Making Prostate Cancer Easier to Understand for Newly Diagnosed Patients

Ryan Scott
Dr. Ravi Munver explained that, for patients who are recently diagnosed with prostate cancer, it is important to explore treatment option with their care.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of two doctors with text.
June 22nd 2025

Experts Impart Notable Information and Updates for Those With Blood Cancers

Dr. Joshua K. Sabari Dr. Nausheen Ahmed
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.
Image of smiley face.
June 20th 2025

Radiation and Resilience: Laughing Through the Hardest Days

Dave Davison
It’s a bad day when a doctor says you have cancer. It’s a worse day when he says it’s stage prostate cancer with a metastatic lesion.
Related Content
Advertisement
Image of prostate model.
June 27th 2025

June Prostate Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data on the role of AI in care.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of Dr. Ravi, with text,
June 26th 2025

Making Prostate Cancer Easier to Understand for Newly Diagnosed Patients

Ryan Scott
Dr. Ravi Munver explained that, for patients who are recently diagnosed with prostate cancer, it is important to explore treatment option with their care.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of two doctors with text.
June 22nd 2025

Experts Impart Notable Information and Updates for Those With Blood Cancers

Dr. Joshua K. Sabari Dr. Nausheen Ahmed
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.
Image of smiley face.
June 20th 2025

Radiation and Resilience: Laughing Through the Hardest Days

Dave Davison
It’s a bad day when a doctor says you have cancer. It’s a worse day when he says it’s stage prostate cancer with a metastatic lesion.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.